Biotech Building ‘Molecular Glues’ AI Platform Raises £3.6m

Why It Matters

Predictable molecular‑glue design could unlock new therapeutic targets, accelerating drug pipelines and reshaping biotech investment landscapes.

Key Takeaways

• Ternary Therapeutics raised £3.6 million seed funding.
• AI platform targets undruggable proteins using molecular glues.
• Combines machine learning, physics modeling, rapid lab validation.
• Design process iteratively improves through experimental feedback loops.
• Investors: daphni, Pace Ventures, i&i Biotech Fund, UK Seed.

Pulse Analysis

The emergence of AI‑powered platforms in drug discovery marks a shift from serendipitous chemistry to systematic engineering. Ternary Therapeutics’ approach leverages deep learning models trained on physics‑derived protein dynamics, enabling the prediction of binding interfaces that traditional high‑throughput screens often miss. By integrating rapid in‑vitro validation, the platform creates a closed‑loop system where experimental outcomes continuously refine the algorithm, shortening the design‑test cycle and reducing R&D costs.

Molecular glues have already demonstrated clinical impact, exemplified by drugs that recruit E3 ligases to degrade disease‑causing proteins. However, their discovery has largely been accidental, limiting broader application. Ternary’s disciplined methodology promises to democratize this modality, expanding the addressable proteome and offering solutions for diseases with few therapeutic options, such as certain cancers and neurodegenerative disorders. The ability to intentionally engineer these bifunctional molecules could also spur novel partnership models between biotech firms and large pharmaceutical companies seeking to diversify their pipelines.

The £3.6 million seed round underscores growing investor confidence in AI‑driven biotech ventures. Backers like daphni and the UK Innovation & Science Seed Fund view the technology as a high‑value differentiator that can generate proprietary asset classes and generate attractive returns. As the platform matures, it may attract strategic collaborations, licensing deals, and further capital to scale preclinical programs, positioning Ternary as a potential leader in the next wave of precision medicine innovation.